MEM 1003

DB05547InvestigationalSmall molecule

MEM 10003 was under investigation in clinical trial NCT00257673 (Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease) for the treatment of Alzheimer's...

Mechanism: Pharmacologically active on Voltage gated L-type calcium channel
Curator reviewed
Primary indication: Investigated for use/treatment in alzheimer's disease, bipolar disorders, dementia, and neurologic disorders.Curator reviewed
Also known as: CALCIUM CHANNEL, L TYPE, ALPHA-1 POLYPEPTIDE, ISOFORM 1, CARDIAC MUSCLE · VOLTAGE-DEPENDENT L-TYPE CALCIUM CHANNEL SUBUNIT ALPHA-1C · VOLTAGE-GATED CALCIUM CHANNEL SUBUNIT ALPHA CAV1.2
Code names: CACH2 · CACN2 · CACNA1C · CACNL1A1 · CCHL1A1

Resolves to

Compound

UNIIZ0TN07HN7X

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of MEM 1003, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account